Communiqués Relmada Therapeutics, Inc. OTC Markets

Actions

RLMD

US75955J4022

Recherche biotechnologique et médicale

Temps Différé OTC Markets Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		+8,91%	+139,13%

28/07	Relmada Therapeutics, Inc. annonce la nomination de Bipin Dalmia au poste de Chief Business Officer	CI
29/06	Relmada Therapeutics intègre les indices Russell 2000 et Russell 3000	MT

Communiqués

28/07	Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer	AQ
16/07	Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026	AQ
29/06	Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes	AQ
11/06	Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program	AQ
28/05	Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference	AQ
15/05	Relmada Therapeutics : NDV-01 AUA 2026 Poster	PU
12/05	Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
06/05	Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026	AQ
05/05	Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026	AQ
19/03	Relmada Therapeutics : NDV-01 12-Month Phase 2 Data	PU
19/03	Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update	AQ
12/03	Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026	AQ
09/03	Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference	AQ
09/03	Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing	AQ
09/03	Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer	AQ
12/01	Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications	AQ
04/12	Relmada Therapeutics : SUO 2025 Poster Presentation	PU
03/12	Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology	AQ
13/11	Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates	AQ
07/11	Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025	AQ
04/11	Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	AQ
04/11	Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer	AQ
07/10/25	Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01	AQ
16/09/25	Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
11/09/25	Relmada Therapeutics Issues Mid-Year CEO Letter to Shareholders	AQ